Compare ARK Genomic Revolution ETF (ARKG) vs Jabil Inc (JBL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Jabil Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Jabil Inc trades at $328 (market cap $34.61B). The key difference: Jabil Inc pays a 0.1% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Jabil Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | JBL | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $385.50 |
52-Week Low | $23.09 | $192.49 |
Market Cap | — | $34.61B |
Enterprise Value | — | $37.14B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
JBL trades at $330.29, down 0.67% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with revenue growth from $29.8B in 2025 to $33.6B projected for 2026, and net income rising from $657M to $862M. Analyst consensus is split evenly between Buy and Hold ratings with a $436.50 price target, representing 32% upside potential. Recent news highlights JBL's expansion in AI infrastructure manufacturing and healthcare technologies.
JBL presents a compelling growth story driven by AI infrastructure demand and manufacturing expansion, though valuation metrics appear elevated with a P/E of 41.34. The primary risk involves execution of growth initiatives amid competitive pressures. Technical indicators suggest near-term consolidation near support levels, while fundamental strength supports long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
